Gpr116 a novel potential therapeutic target for breast cancer treatment

Abstract

This current research focused on finding a ligand for GPR116 an newlineorphan receptor, that could be a target for therapy of Triple Negative Breast newlineCancer (TNBC). Breast Cancer (BCs) is the second most common cancer newlineworldwide, particularly in women. TNBC accounts for approximately 15~20% newlineof all BCs. TNBC is distinguished from other BCs by the lack or nil expressions newlineof ER, HER2 and PR. In addition to that early metastasis, often reversion of newlineclinical manifestations, poor prognosis and limited targeted therapeutic options newlineare significant features of TNBC. Diagnosis and therapy of TNBC are hampered newlinedue to its receptor-negative. Therefore, the only systemic treatment option for newlineTNBC is currently chemotherapy. However, the high genetic variability in newlineTNBC makes targeted therapies ineffective. Therefore, the identification of newlinecommon drug targets is an important task. newlineG Protein Coupled Receptors are seven transmembrane proteins that newlineregulate several cell signaling pathways, cell communication and interaction of newlinecells with their microenvironments. GPCRs are known for their function in newlinedifferent aspects of tumorogenesis such as cell proliferation, cell invasion and newlinemigration, modulation of immune cell function and angiogenesis. Abnormal newlineexpression of GPCRs has been studied in many cancers. A literature study newlinedisclosed that 30 to 50% of currently existing FDA-approved drugs are targeting newlineseveral druggable sites of GPCRs. GPR116 is an orphan adhesion receptor newlineknown for its role in the metastasis of TNBC. However, no ligands for GPR116 newlinehave been approved clinically until now. newline